Xencor | XNCR - Cost Of Sales


Xencor reported $61.66M in Cost of Sales for its fiscal quarter ending in June of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Cytokinetics USD 99.23M 13.32M Sep/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
J&J USD 7.97B 689M Dec/2025
Karyopharm Therapeutics USD 37.43M 2.41M Sep/2024
MacroGenics USD 10.12M 34.18M Dec/2025
Merck USD 3.32B 531M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Xencor USD 61.66M 50.95M Jun/2025